Abstract:DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells.DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen, as well as typical B-cell markers.PROGNOSIS: The two similar clinical staging systems, Rai and Binet, create prognostic information by using results of physical examination and blood counts. Various biological and genetic markers also have prognostic value. Deletions of the short arm of chromosome 17 (del [17p]) and/or mutations of the TP53 gene, predict resistance to chemoimmunotherapy and a shorter time to progression, with most targeted therapies. A comprehensive, international prognostic score (CLL-IPI) integrates genetic, biological and clinical variables to identify distinct risk groups of CLL patients.THERAPY: Only patients with active or symptomatic disease, or with advanced Binet or Rai stages require therapy. When treatment is indicated, several options exist for most CLL patients: a combination of venetoclax with obinutuzumab, ibrutinib monotherapy, or chemoimmunotherapy. For physically fit patients younger than 65 (in particular when presenting with a mutated IGVH gene), chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab remains a standard therapy, since it may have curative potential. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del (17p) or TP53 mutation are a different, high-risk category and should be treated with targeted agents. An allogeneic SCT may be considered in relapsing patients with TP53 mutations or del (17p), or patients that are refractory to inhibitor therapy.FUTURE CHALLENGES: Targeted agents (ibrutinib, idelalisib, venetoclax, obinutuzumab) will be increasingly used in combination to allow for short, but potentially definitive therapies of CLL. It remains to be proven that they generate a superior outcome when compared to monotherapies with inhibitors of Bruton tyrosine kinase, which can also yield long-lasting remissions. Moreover, the optimal sequencing of drug combinations is unknown. Therefore, CLL patients should be treated in clinical trials whenever possible.

T‐cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments

T-cell prolymphocytic leukemia: a single-institution experience

Fighting physics: a tough battle

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

Constrained off-line synthesis approach of model predictive control for networked control systems with network-induced delays.

Factors influencing protein tyrosine nitration--structure-based predictive models.

Recent Advances in the Treatment of Peripheral T-Cell Lymphoma

Clinical Features and Outcomes of Plasma Cell Leukemia: A Single-Institution Experience in the era of Novel Agents

Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene

Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma.

Effect of the M(s) transformation temperature on the wear behaviour of NiTi shape memory alloys for articular prosthesis.

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Peripheral T-cell lymphoma: From biology to practice to the future

From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature

Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment

Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia

Research Progress of T Cell Lymphoma: Reports from 2014 International Conference on T Cell Lymphoma in Clinical Treatment

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

How I treat the peripheral T-cell lymphomas

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma